A synthetic analogue of growth hormone-releasing hormone (GHRH) studied through the GHRH receptor and downstream GH/IGF-1 axis. Research areas include endocrine signalling, growth-hormone physiology and metabolic regulation.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
(FDA approved)
Tesamorelin is a synthetic peptide analogue of human growth hormone-releasing hormone (GHRH). It consists of 44 amino acids and contains a structural modification designed to improve its stability compared with naturally occurring GHRH.
It acts by binding to GHRH receptors in the anterior pituitary gland, stimulating the secretion of endogenous growth hormone (GH). Growth hormone subsequently influences several physiological pathways, including insulin-like growth factor-1 (IGF-1) production, lipid metabolism and tissue regulation.
Tesamorelin has been extensively investigated in clinical research examining growth hormone secretion, visceral adipose tissue metabolism and metabolic regulation. Its ability to stimulate the body’s endogenous GH–IGF-1 axis distinguishes it from compounds that directly supply exogenous growth hormone.
Clinical studies have demonstrated reductions in visceral adipose tissue in specific patient populations. Tesamorelin have an established medical application for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Tesamorelin 10 mg is presented as a research peptide for laboratory and scientific applications. The stated quantity refers to the amount of peptide contained in the product and should not be interpreted as a recommended human dosage.
Product: Tesamorelin
Strength: 10 mg
Category: Growth Hormone
Compound classification: Synthetic 44-amino-acid peptide; growth hormone-releasing hormone analogue
Research target: Growth hormone-releasing hormone receptors (GHRHR) in the anterior pituitary gland
Research focus: Growth hormone secretion, GH–IGF-1 axis regulation, visceral adipose tissue metabolism, lipid metabolism and body composition
Mechanism: Activates pituitary GHRH receptors, stimulating endogenous growth hormone secretion and subsequent IGF-1 production
Intended use: Laboratory and research use only
A synthetic growth hormone secretagogue peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone signalling pathways. Its research landscape includes GH secretion, neuroendocrine regulation and metabolic signalling.
A synthetic growth hormone-releasing peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone secretory pathways. Its research landscape includes GH release, pituitary signalling and neuroendocrine regulation.
A two-component research formulation combining a GHRH-pathway analogue with a growth-hormone secretagogue, allowing investigation of two distinct signalling mechanisms converging on the GH axis. Both components and their quantities should remain explicitly identified.
A synthetic fragment derived from the C-terminal region of human growth hormone. Research focuses on the biological properties of this fragment and its relationship to metabolic and GH-associated signalling without representing the complete GH molecule.
A short-acting GHRH-analogue research peptide used to investigate growth-hormone-releasing pathways and GH/IGF-1 signalling. The No-DAC form must be clearly distinguished from albumin-binding CJC-1295 with DAC because their molecular designs are not equivalent.
A growth-hormone secretagogue investigated through ghrelin/GHS receptor signalling and downstream GH physiology. It provides a mechanistically different research route into the GH axis than GHRH analogues such as CJC-1295 and tesamorelin.